Discovery of Novel Isatin-Based p53 Inducers.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  ACS Medicinal Chemistry Letters

• Publication date

  2015-07-09

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/acsmedchemlett.5b00011PMID 26288684PMCID PMC4538431
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Corrigendum to "Discovery of orally active anticancer candidate CFI-400945 derived from biologically promising spirooxindoles: Success and challenges" [Eur. J. Med. Chem. 95 (2015) 35-40].

  2016cited by this paper
• Drug discovery using spirooxindole cores: Success and Challenges [corrected].

  2015cited by this paper
• Development of Selective Inhibitors for Aldehyde Dehydrogenases Based on Substituted Indole-2,3-diones

  2014cited by this paper
• Targeting the MDM2–p53 Protein–Protein Interaction: Design, Discovery, and Development of Novel Anticancer Agents

  2014cited by this paper
• Caught in the cross fire: p53 in inflammation.

  2014cited by this paper
• Mannich bases in medicinal chemistry and drug design

  2014cited by this paper
• Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment

  2014cited by this paper
• First X-ray structural characterization of isatin Schiff base derivative. NMR and theoretical conformational studies

  2014cited by this paper
• Drugging the p53 pathway: understanding the route to clinical efficacy

  2014cited by this paper
• Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.

  2014cited by this paper
• MOZ increases p53 acetylation and premature senescence through its complex formation with PML

  2013cited by this paper
• Recent highlights in the development of isatin- based anticancer agents

  2013cited by this paper
• Molecular dynamics of the full-length p53 monomer

  2013cited by this paper
• Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53

  2013cited by this paper
• Lysine-specific modifications of p53: a matter of life and death?

  2013cited by this paper
• The structure of an MDM2-Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant.

  2013cited by this paper
• Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

  2013cited by this paper
• Synthesis, in vitro, and in cell studies of a new series of [indoline-3,2'-thiazolidine]-based p53 modulators.

  2013cited by this paper
• New anticancer agents mimicking protein recognition motifs.

  2013cited by this paper
• Identification of FDA‐approved Drugs that Computationally Bind to MDM2

  2012cited by this paper
• Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression.

  2011cited by this paper
• Recent advances in the therapeutic perspectives of Nutlin-3.

  2011cited by this paper
• Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin‐3 in gastric cancer cells

  2011cited by this paper
• Synthesis and evaluation of isatin analogs as caspase-3 inhibitors: introduction of a hydrophilic group increases potency in a whole cell assay.

  2011cited by this paper
• Heterochromatin silencing at p53 target genes by a small viral protein

  2010cited by this paper
• Hybrid pharmacophore design and synthesis of isatin-benzothiazole analogs for their anti-breast cancer activity.

  2009cited by this paper
• Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft.

  2008cited by this paper
• Selective inhibition of carboxylesterases by isatins, indole-2,3-diones.

  2007cited by this paper
• p53 ubiquitination: Mdm2 and beyond.

  2006cited by this paper
• p53 Activation by small molecules: application in oncology.

  2005cited by this paper
• In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

  2004cited by this paper
• p53 and apoptosis: it's not just in the nucleus anymore.

  2003cited by this paper
• Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases.

  2001cited by this paper

• Novel Dehydroabietylamine C-Ring Schiff Base Derivatives: Synthesis, Antiproliferative activity, DNA binding and Molecular docking.

  2025cites this paper
• Synthesis of novel 4-substituted isatin Schiff base derivatives as potential autophagy inducers and evaluation of their antitumour activity

  2024cites this paper
• Lipoxygenases at the Intersection of Infection and Carcinogenesis

  2024cites this paper
• At the Crossroads of the cGAS-cGAMP-STING Pathway and the DNA Damage Response: Implications for Cancer Progression and Treatment

  2023cites this paper
• Flaviviruses in AntiTumor Therapy

  2023cites this paper
• Non-Immunoglobulin Synthetic Binding Proteins for Oncology

  2023cites this paper
• Strategies for Engineering of Extracellular Vesicles

  2023cites this paper
• BRCA Mutations—The Achilles Heel of Breast, Ovarian and Other Epithelial Cancers

  2023cites this paper
• p53 Affects Zeb1 Interactome of Breast Cancer Stem Cells

  2023cites this paper
• Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets.

  2023cites this paper
• The Role of p53 in Nanoparticle-Based Therapy for Cancer

  2023cites this paper
• Anticancer Activity of Mannich Bases: A Review of Recent Literature

  2022cites this paper
• Design, synthesis, and molecular modeling of coumarin derivatives as MDM2 inhibitors targeting breast cancer

  2022cites this paper
• The Role of Lysine Methyltransferase SET7/9 in Proliferation and Cell Stress Response

  2022cites this paper
• The Role of E3 Ligase Pirh2 in Disease

  2022cites this paper
• Development of Isatin‐Based Schiff Bases Targeting VEGFR‐2 Inhibition: Synthesis, Characterization, Antiproliferative Properties, and QSAR Studies

  2022cites this paper
• NEK2, a promising target in TP53 mutant cancer

  2022cites this paper
• Opposing Roles of Wild-type and Mutant p53 in the Process of Epithelial to Mesenchymal Transition

  2022cites this paper
• IN VITRO AND IN SILICO CYTOTOXICITY EVALUATION OF SOME ISATIN MANNICH BASES ON HUMAN MELANOMA CELLS

  2022cites this paper
• Artificial genetic polymers against human pathologies

  2022cites this paper
• Alpha-actnin-4 (ACTN4) selectively affects the DNA double-strand breaks repair in non-small lung carcinoma cells

  2022cites this paper
• Anticancer Compounds Based on Isatin-Derivatives: Strategies to Ameliorate Selectivity and Efficiency

  2021cites this paper
• 3′,4′-Dihydro-2′H-spiro[indoline-3,1′-isoquinolin]-2-ones as potential anti-cancer agents: synthesis and preliminary screening

  2020cites this paper
• Hydrolysis of Schiff bases with phenyl-ethynyl-phenyl system: The importance for biological and physicochemical studies.

  2020cites this paper
• Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy

  2020cites this paper
• Isatin derivatives as DNA minor groove-binding agents: a structural and theoretical study

  2020cites this paper
• Synthesis and synergistic studies of isatin based mixed ligand complexes as potential antifungal therapeutic agents

  2019cites this paper
• Synthesis of isatin based N1-alkylated 3-β-C-glycoconjugated-oxopropylidene oxindoles as potent antiplasmodial agents.

  2019cites this paper
• Structure and catalytic properties of novel copper isatin Schiff base complexes

  2019cites this paper
• Regulation of p53 Protein Function in Response to Heat Shock

  2019cites this paper
• Novel Isatin-based activator of p53 transcriptional functions in tumor cells

  2019cites this paper
• Simulation of MDM2 N-terminal domain conformational lability in the presence of imidazoline based inhibitors of MDM2-p53 protein–protein interaction

  2019cites this paper
• Design, in silico prioritization and biological profiling of apoptosis-inducing lactams amenable by the Castagnoli-Cushman reaction.

  2018cites this paper
• Isatin-Schiff base-copper (II) complex induces cell death in p53-positive tumors

  2018cites this paper
• Novel isatin-derived molecules activate p53 via interference with Mdm2 to promote apoptosis

  2018influential citation
• The molecular structure of 5-X-isatines where (X = F, Cl, and Br) determined by gas-phase electron diffraction with theoretical calculations

  2018cites this paper
• A Study on Hydrolytic Stability of Isatin N-Mannich Bases

  2018cites this paper
• Proapoptotic modification of substituted isoindolinones as MDM2-p53 inhibitors.

  2017cites this paper
• Xth International Conference of Young Scientists in Chemistry “Mendeleev-2017.” Section “Bioorganic and Medicinal Chemistry”

  2017cites this paper
• Conformational stabilization of isatin Schiff bases – biologically active chemical probes

  2017cites this paper
• Spirooxindoles as novel 3D-fragment scaffolds: Synthesis and screening against CYP121 from M. tuberculosis.

  2016cites this paper
• Diastereotopic derivatives of chiral alkoxyisoindolinones

  2016cites this paper